PMID- 2866057
OWN - NLM
STAT- MEDLINE
DCOM- 19860123
LR  - 20151119
IS  - 0265-5985 (Print)
IS  - 0265-5985 (Linking)
VI  - 2
IP  - 3
DP  - 1985 May
TI  - The effect of non-specific beta-blockade on metabolic and haemostatic variables 
      during hypoglycaemia.
PG  - 127-34
AB  - Several haemostatic and metabolic variables were monitored during insulin stress 
      tests (ISTs), which were preceded by placebo, nadolol or propranolol ingestion 
      for 10 days. Nadolol administration blocked the rise in plasma factor VIII: RAg 
      concentrations, but no significant changes were observed in platelet 
      aggregation/thromboxane A2 release. Propranolol administration reduced the 
      significance, but not the magnitude, of the plasma factor VIII:Rag rise and also 
      marginally inhibited platelet aggregation/TXA2 release. Both nadolol and 
      propranolol inhibited the hypokalaemia of hypoglycaemia and retarded the recovery 
      of plasma glucose concentrations, probably by inhibiting lipolysis (as indicated 
      by serum nonesterified fatty acid concentrations). Both nadolol and propranolol 
      often masked and delayed the onset of the symptoms of hypoglycaemia. 
      Beta-blockers may exert beneficial effects by modifying haemostatic variables and 
      by preventing hypokalaemia during stressful situations, such as hypoglycaemia or 
      myocardial infarction, both in diabetics and in non-diabetics. However, any 
      benefit must be balanced against the risk of masking, and possibly increasing the 
      incidence of, hypoglycaemia in diabetics.
FAU - Mikhailidis, D P
AU  - Mikhailidis DP
FAU - Barradas, M A
AU  - Barradas MA
FAU - Hutton, R A
AU  - Hutton RA
FAU - Jeremy, J Y
AU  - Jeremy JY
FAU - Sabur, M
AU  - Sabur M
FAU - Dandona, P
AU  - Dandona P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Diabetes Res
JT  - Diabetes research (Edinburgh, Scotland)
JID - 8502339
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Insulin)
RN  - 0 (Propanolamines)
RN  - 42200-33-9 (Nadolol)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9001-27-8 (Factor VIII)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - RWP5GA015D (Potassium)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adrenergic beta-Antagonists/*pharmacology
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - Blood Platelets/metabolism
MH  - Blood Pressure/*drug effects
MH  - Factor VIII/analysis
MH  - Fatty Acids, Nonesterified/blood
MH  - Female
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Hypoglycemia/*physiopathology
MH  - *Insulin
MH  - Kinetics
MH  - Male
MH  - Nadolol
MH  - Platelet Aggregation/drug effects
MH  - Potassium/blood
MH  - Propanolamines/*pharmacology
MH  - Propranolol/*pharmacology
MH  - Pulse/*drug effects
MH  - Thromboxane B2/blood
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
PST - ppublish
SO  - Diabetes Res. 1985 May;2(3):127-34.